US Executive Compensation Proxy SEC Filings — September 25, 2026

25-09-2026

Oracle Corporation filed its definitive proxy statement (DEF 14A) on September 25, 2026, for the 2026 Annual Meeting of Stockholders to be held virtually on November 18, 2026. The meeting will include the election of 13 director nominees, an advisory vote on executive compensation, ratification of Ernst & Young LLP as auditor for fiscal 2027, and a stockholder proposal on preserving shareholder proposal access rights. The filing details executive compensation for fiscal 2026, including equity awards and pay practices, but does not disclose specific financial performance metrics or period-over-period comparisons.

• · The proxy statement was first made available to stockholders on or about September 25, 2026.
• · Fiscal 2026 began June 1, 2025 and ended May 31, 2026; fiscal 2027 began June 1, 2026.
• · The record date for voting is September 21, 2026.
• · Stockholders may submit one question in advance or during the meeting via the virtual platform.
• · A replay of the meeting will be available through November 25, 2026.

25-09-2026

Texas Pacific Land Corp (TPL) filed its DEF 14A proxy statement for the 2026 Annual Meeting, scheduled for November 5, 2026, in Dallas, Texas. The Board recommends voting FOR all four proposals, including the election of nine directors, advisory approval of executive compensation, ratification of Deloitte as auditor, and a proposed redomestication from Delaware to Texas. As of the September 10, 2026 record date, 68,974,683 shares of common stock were issued and outstanding.

• · Annual Meeting to be held at Marriott Dallas Uptown, 3033 Fairmount Street, Dallas, Texas 75201 at 11:00 a.m. Central Time.
• · Internet and telephone voting close at 10:59 p.m. Central Time on November 4, 2026; mailed proxy cards must be received by November 4, 2026.
• · Proposal 4 (redomestication) requires affirmative vote of a majority of outstanding shares; abstentions and broker non-votes count as votes against.
• · Proposals 1, 2, and 4 are considered 'non-routine' matters; Proposal 3 (auditor ratification) is 'routine'.
• · The Delaware Charter prohibits cumulative voting in the election of directors.
• · Questions for the annual meeting can be submitted by email to [email protected] until 11:59 p.m. Central Time on November 4, 2026.

25-09-2026

25-09-2026

OFA Group filed a DEF 14A proxy statement for its 2026 Annual Meeting on October 5, 2026, with 10 proposals including director re-elections, auditor ratification, multiple share consolidation and authorized capital increases, and an ELOC facility of up to $100M. The company has a dual-class structure where three insiders (CEO, CTO, and one other) control ~98.88% of voting power despite owning only ~11.95% of Class A shares and 100% of Class B shares. While the ELOC provides potential liquidity, the heavy dilution risk from multiple consolidation and capital increase proposals and the extreme insider control concentration are significant governance concerns.

• · The company is a Cayman Islands exempted company.
• · Principal executive office: 609 Deep Valley Drive, Suite 200, Rolling Hills, CA 90274.
• · Annual Meeting will be held on October 5, 2026 at 2:00 P.M. Pacific Time.
• · Record Date for voting: September 17, 2026.
• · Class B ordinary shares carry 25 votes per share; Class A ordinary shares carry 1 vote per share.
• · Proposal 3 (Third M&AA Ratification) relates to a previously approved 10-for-1 consolidation of Class A shares at an EGM on May 21, 2026.
• · Proposal 5 seeks to increase authorized share capital from $320,000 to $22,520,000.
• · Proposal 7 allows the Board to effect one or more share consolidations of Class A shares at ratios between 2-for-1 and 25-for-1, at its discretion, over the next year.
• · Proposal 9 (ELOC) requires approval under Nasdaq Listing Rule 5635(d) because it involves issuance of more than 20% of outstanding shares.
• · Quorum requires holders of at least one-third of issued and outstanding ordinary shares (8,817,828 shares).
• · Broker non-votes will have no effect on any proposal except the Auditor Ratification Proposal (considered routine).
• · All proposals require a simple majority of votes cast, except Proposals 3, 6, and 8 which require at least two-thirds of votes cast (special resolutions).

25-09-2026

CVD Equipment Corporation filed its definitive proxy statement for the 2026 Annual Meeting of Shareholders, to be held virtually on November 5, 2026. The meeting will include the election of five directors, ratification of CBIZ CPAs P.C. as independent auditor, and a non-binding advisory vote on executive compensation. As of the record date, 6,951,203 shares of common stock were outstanding, and the company is soliciting proxies with a recommendation to vote FOR all proposals.

• · Annual Meeting to be held virtually via live webcast at 10:00 A.M. Eastern Time on November 5, 2026.
• · Record date for voting is September 16, 2026.
• · Proxy materials distributed on or about September 25, 2026.
• · Proposal 2 (ratification of auditor) is considered a 'routine' matter, allowing broker discretionary voting.
• · Proposals 1 and 3 are non-routine, so brokers will not have discretionary authority to vote on them.
• · Shareholders can vote via proxy card, internet (by 11:59 p.m. ET on November 4, 2026), or during the virtual meeting.
• · The company will reimburse brokerage firms for forwarding solicitation materials to beneficial owners.
• · Householding practice may result in only one copy of proxy materials being sent to multiple shareholders in a household.

25-09-2026

Dolphin Entertainment, Inc. filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Shareholders, scheduled for November 4, 2026. The Board of Directors, currently composed of seven members, has nominated all seven incumbent directors for re-election, including CEO/Chairman William O’Dowd, IV and CFO/COO Mirta A. Negrini. The filing also discloses that the Board held only three meetings in 2025 and does not perform a risk oversight function, and that only two of seven directors attended the prior year's annual meeting.

• · The Board does not have a formal policy on separating the Chairman and CEO roles; currently they are combined.
• · The Board does not perform a risk oversight function.
• · No family relationships exist among directors or executive officers.
• · No director or executive officer has been involved in any of the specified legal proceedings (bankruptcy, criminal conviction, securities violations, etc.) in the past ten years.

25-09-2026

Lifeward Ltd. filed a DEF 14A proxy statement for its 2026 Annual General Meeting, seeking shareholder approval for the re-election of Class III directors Haggai Zamir and Avraham Gabay. The filing details significant corporate events, including the March 2026 acquisition of Oratech Pharma, Inc. from Oramed, which resulted in the issuance of 2,256,476 ordinary shares and pre-funded warrants, representing 45.0% of outstanding shares post-closing, and subsequent board changes. The proxy also notes a sharp decline in the company's stock price from $14.76 on June 4, 2025 to $7.60 on August 15, 2025, reflecting a 48.5% drop.

• · The proxy statement is first being mailed on or about October 7, 2026.
• · Shareholders may submit position statements on agenda items by October 20, 2026.
• · The board was increased from five to eight seats in connection with the Oratech Acquisition.
• · Quarterly revenue sharing payments based on sales of ReWalk Personal Exoskeleton products and related extended warranties are part of the consideration to Oramed.
• · The stock price dropped from $14.70 on June 2, 2025 to $8.60 on August 13, 2025, a 41.5% decline, before further falling to $7.60 on August 15, 2025.

25-09-2026

Pulmatrix, Inc. is proposing a merger with Eos SENOLYTIX Inc. via a reverse merger structure where Merger Sub (a Pulmatrix subsidiary) will merge into Eos, making Eos a wholly owned subsidiary of Pulmatrix. The combined company will prioritize Eos's preclinical geropeptide pipeline targeting aging-related conditions, while continuing Pulmatrix's iSPERSE™ dry powder delivery platform as a business stream. Pulmatrix stockholders will receive approximately 6% ownership in the combined entity. The merger is motivated by Pulmatrix's inability to secure funding for its own pipeline and a decline in biotech financing, while Eos seeks public market access. The proxy also includes a reverse stock split proposal. No specific financial figures are disclosed in this excerpt.

• · Pulmatrix's PUR3100 received FDA IND acceptance for a Phase 2 study and a direct-to-Phase 3 pathway is being explored; Pulmatrix is seeking a licensing partner for this product.
• · Pulmatrix's partner Cipla has been approved to commence a Phase 3 trial in India for PUR1900; Pulmatrix will receive 2% royalties on net sales outside the U.S. and shares 50%/50% on U.S. development.
• · PUR1800 has completed Phase 1 but is dependent on a third-party license.
• · Eos is in preclinical stage with IND-enabling studies for PTC-2105; no clinical trials have started.
• · The merger is structured as a tax-free reorganization under Section 368(a) of the Internal Revenue Code for Eos stockholders; Pulmatrix stockholders will not recognize gain or loss on the reverse stock split except for cash in lieu of fractional shares.
• · Pulmatrix directors and officers have interests in the merger including continued indemnification and insurance, and outstanding warrants will survive the closing.

25-09-2026

IX Acquisition Corp. filed a DEF 14A proxy statement on September 25, 2026, seeking shareholder approval for a fifth extension of the deadline to complete a business combination (Fifth Extension Amendment Proposal), ratification of auditors, and an adjournment proposal. The meeting is scheduled for October 7, 2026, with a redemption deadline of October 5, 2026. The sponsor, officers, directors, and anchor investors collectively own 89.13% of the outstanding ordinary shares and can approve the auditor ratification and adjournment proposals without other shareholders' votes, but the extension proposal requires a majority of the public shareholders' votes. The company faces risks including potential classification as an investment company under the Investment Company Act, which could force liquidation, and the possibility that redemptions may leave insufficient cash to complete a business combination.

• · Redemption deadline for public shares is October 5, 2026 at 5:00 p.m. Eastern Time.
• · Meeting date is October 7, 2026.
• · Shareholders must request proxy materials by October 1, 2026 for timely delivery.
• · The company instructed the trustee to liquidate trust account investments on November 13, 2023, moving funds to an interest-bearing demand deposit account to mitigate Investment Company Act risk.
• · Less than 20% of direct and indirect minority investors in the sponsor are non-US persons.
• · The company has filed multiple amendments to its S-4 registration statement (May 13, 2024; amended Sept 30, Oct 28, Nov 25, 2024; Feb 14, 2025).

25-09-2026

Ekso Bionics Holdings, Inc. (now ChronoScale Holdings Corporation) filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders to be held virtually on November 6, 2026. The filing details the company's post-business combination structure, which now operates through two wholly-owned subsidiaries: ChronoScale Corporation (cloud services) and Ekso Bionics, Inc. (exoskeletons). The proxy statement includes proposals for director elections, executive compensation, and other routine matters. No financial results are disclosed in this filing.

• · Annual Meeting to be held on November 6, 2026, at 12:00 p.m. Eastern Time, virtually via the Internet.
• · Holding Company Transaction completed on July 1, 2026, under Section 92A.134 of the Nevada Revised Statutes, without stockholder approval.
• · Proxy materials available at www.proxyvote.com and www.sec.gov.
• · Cloud services provided at third-party colocation centers in Colorado, Minnesota, and Utah.
• · The proxy statement includes proposals for director elections, executive compensation, and other routine matters.

25-09-2026

Greene County Bancorp Inc. filed its definitive proxy statement (DEF 14A) for the 2026 annual meeting, detailing board composition, committee functions, and governance policies. The board is chaired by independent Director Jay Cahalan, and all directors except Donald Gibson, James Schaefer, and Michelle Plummer are deemed independent under Nasdaq rules. The company has not granted stock options historically and maintains strict anti-hedging and anti-pledging policies, with no exceptions approved to date.

• · All directors attended at least 75% of aggregate Board and Committee meetings during fiscal 2026.
• · All directors attended the 2025 Annual Meeting of Shareholders in person.
• · The Executive Committee did not meet during fiscal 2026.
• · The Nominating Committee met once during fiscal 2026.
• · The Compensation Committee met five times during fiscal 2026.
• · The company is a 'controlled company' under Nasdaq rules, exempt from requiring a fully independent Nominating Committee.
• · Michelle Plummer will become independent effective July 1, 2027.
• · No stock options were granted during fiscal 2026, and the company does not expect to grant them in the future.
• · The company has no formal diversity policy for director nominees.
• · Stockholders may submit director nominations to the Corporate Secretary at least 90 days before the anniversary of the prior year's proxy mailing date.

25-09-2026

Super League Enterprise, Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting, seeking stockholder approval for a transformative transaction with Metaplanet, a subsidiary of Metaplanet Parent (TSE: 3350 / OTCQX: MTPLF). Under the Subscription Agreements, Metaplanet will invest 2,100 Bitcoin (valued at the August 14, 2026 market price) plus $2,500,000 in cash in exchange for common stock at $3.00 per share, with a five-year lock-up. The Board unanimously recommends approval, citing the creation of a substantial Bitcoin treasury, the largest capital investment in Super League's history, and strategic benefits including access to Metaplanet's expertise in custody, accounting, and Bitcoin income generation. However, the filing acknowledges Super League's history of operating losses, liquidity challenges, and the risk that Bitcoin's price could decline substantially before closing, which would reduce the effective per-share consideration.

• · The Super League Board did not conduct a formal market check, auction, or other solicitation process prior to approving the Metaplanet Transaction.
• · The Board considered discussions with more than six alternative digital asset treasury companies in 2025, none of which were formally pursued to a definitive stage.
• · The Board considered the alternative of remaining a standalone operating company without a Bitcoin treasury and concluded the Metaplanet Transaction presented a more compelling opportunity.
• · The filing notes Super League's history of operating losses, its liquidity position and anticipated capital requirements, and the execution risks associated with management's growth initiatives.
• · The lock-up period for Metaplanet is five years from the date of Closing.

25-09-2026

Weave Communications, Inc. has filed a definitive proxy statement (DEFM14A) for a special meeting of stockholders to vote on a proposed acquisition by affiliates of Francisco Partners. Under the Merger Agreement dated August 18, 2026, stockholders will receive $7.40 per share in cash. The Board unanimously recommends voting 'FOR' the merger and the adjournment proposal, with the special meeting scheduled for October 22, 2026.

• · The special meeting will be held virtually on October 22, 2026 at 10:00 a.m. Eastern Time.
• · Record date for voting is September 14, 2026.
• · Stockholders who do not vote in favor have the right to seek appraisal of the fair value of their shares under Delaware law.
• · The Merger Agreement is attached as Annex A to the proxy statement.
• · The proxy statement is first being distributed on or about September 25, 2026.